Close Menu

This story has been updated with information from a conference call with NeoGenomics executives discussing the financial results.

NEW YORK – NeoGenomics Tuesday reported a 14 percent year-over-year decline in its second quarter revenues due to fallout from the COVID-19 pandemic.

For the three months ended June 30, total revenues reached $87.0 million, down from $101.7 million in Q2 2019, and slightly beating analysts' average estimate of $86.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.